Clinical trials
Localized Prostate Cancer clinical trials
Below are recruiting localized prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 495 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07824349RecruitingPhase 1
JUR-003 for metastatic prostate cancer
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT03294889RecruitingPhase 1/Phase 2
Single-dose SBRT for early prostate cancer
This trial tests a very short, one-time form of radiation (SBRT) to treat prostate cancer. It aims to see whether treating the prostate in one shot is safe and effective for carefully selected patients.
GenevaAges 18–85 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT04231006Recruiting
High-dose salvage radiation for prostate cancer that came back locally
This trial studies high-dose radiation (HDR) given after prostate cancer returns only in the prostate/seminal vesicles. It may help by trying to control the cancer when it has not spread elsewhere, using targeted treatment based on MRI and biopsy proof.
Aarhus, Region MidtAges 18 years+ - NCT05010343RecruitingPhase 2
Carbon ion radiation guided by scans for prostate cancer
This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.
ShanghaiAges 45–85 - NCT05163197Recruiting
Registry for laser treatment of localized prostate cancer
This is a registry study that collects information from men with localized prostate cancer who receive transperineal laser ablation (a procedure done through the skin between the scrotum and anus). It may help doctors better understand outcomes and refine treatment choices over time.
AmsterdamAges 18 years+ - NCT02102477Recruiting
Surgery or radiation for prostate cancer in the pelvis
This trial compares surgery versus radiation for men with locally advanced prostate cancer that has not spread to distant sites. It aims to see which treatment works better and is easier to manage for people like you.
AalborgAges 18–75 - NCT04894188Recruiting
Hormone plus radiation before prostate surgery for high-risk cancer
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Douliu City/Huwei Township, Yunlin CountyAges 20–75 - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT05557604RecruitingPhase 2
Tested a targeted prostate cancer radiation plan for higher-risk patients
This Phase 2 trial studies whether a specific radiation approach (including detailed targeting and tracking) can work better for men with intermediate-risk to high-risk prostate cancer. You may be eligible if your scans show no spread beyond the prostate area and you can safely complete the required imaging and treatments.
Rome, LazioAges 18–90 - NCT05597852Recruiting
Rectal gel spacer to help repeat prostate radiation
This trial studies whether placing a soft gel spacer near the rectum can make “salvage” prostate radiation safer and more tolerable when prostate cancer comes back locally. It may help reduce side effects by creating extra space between the rectum and the radiation area.
Toronto, OntarioAges 18 years+ - NCT05698576Recruiting
Laser treatment through the skin for men with prostate cancer
This trial tests a laser procedure done through the skin between the scrotum and anus, guided by MRI and ultrasound, for men with certain prostate cancer types. It aims to heat and treat prostate cancer while checking safety and outcomes over follow-up visits.
Hialeah, FloridaAges 50–80 - NCT03836196Recruiting
Improve treatment for advanced prostate cancer with careful planning
This study looks at how to best plan and deliver treatment for men with advanced local prostate cancer. It may help find the most effective approach while keeping side effects manageable.
Vancouver, British ColumbiaAges 18 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT05019846RecruitingPhase 3
Radiation alone versus radiation plus hormone therapy for prostate cancer
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Brescia, BSAges 18–80 - NCT04549688Recruiting
Active surveillance with focused ultrasound for prostate cancer
This trial studies whether a high-intensity focused ultrasound treatment can help people with localized prostate cancer while still avoiding traditional full-dose treatment for some patients. It may be an option for certain intermediate-risk cases where the cancer is confined to the prostate.
Tønsberg, VestfoldAges 18–80 - NCT05851365RecruitingEarly Phase 1
MRI scan to measure prostate acidity before surgery
This study tests a new MRI technique that measures acidity in prostate tumors. It may help doctors better understand the cancer before surgery, potentially guiding treatment decisions.
San Francisco, CaliforniaAges 18 years+ - NCT07860528Recruiting
High-dose brachytherapy for prostate cancer that has returned
This trial tests a type of radiation therapy called high-dose-rate brachytherapy, which is given to men whose prostate cancer has come back after their first treatment. It aims to control the cancer while keeping side effects low.
Benidorm, AlicanteAges 18 years+ - NCT06270043Recruiting
Focal therapy study for early-stage prostate cancer
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
La Jolla, CaliforniaAges 18 years+ - NCT06305832RecruitingPhase 2
Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Nanjing, JiangsuAges 40 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+
Hear when a new Localized Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized prostate cancer?
- Yes. Clin2 currently lists 495 recruiting localized prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.